title: High-power potassium-titanyl-phosphate photoselective laser vaporization of prostate for treatment of benign prostatic hyperplasia in men with large prostates.
abstract: OBJECTIVE
  To study the safety and efficacy of high-power potassium-titanyl-phosphate photoselective laser vaporization of the prostate in men with prostate volumes greater than 60 cm3.
  
  
  METHODS
  A total of 64 men with symptomatic benign prostatic hyperplasia and large-volume prostates underwent photoselective laser vaporization of the prostate between May 2002 and September 2003. Medical therapy had failed in all men, and 18 presented with urinary retention. The preoperative evaluation included the maximal flow rate, postvoid residual urine volume, prostate volume, serum sodium, creatinine, and hematocrit, and International Prostate Symptom Score. Transurethral prostatectomy was performed with an 80 W potassium-titanyl-phosphate (KTP) side-firing laser system through a 23F continuous-flow cystoscope with normal saline as the irrigant. The operative time, anesthesia type, length of stay, and postoperative serum sodium, creatinine, and hematocrit were recorded. The International Prostate Symptom Score, maximal flow rate, and postvoid residual urine volume were measured at each follow-up visit.
  
  
  RESULTS
  The mean preoperative prostate volume was 101 +/- 40 cm3. The mean operative time was 123 +/- 70 minutes. No transfusions were required. Of the 64 patients, 62 were discharged within 23 hours. The serum sodium level did not change significantly. The International Prostate Symptom Score decreased from 18.4 preoperatively to 9.9, 8.6, 7.2, and 6.7 at 1, 3, 6, and 12 months postoperatively, and the maximal flow rate increased from 7.9 mL/s preoperatively to 16.4, 16.2, 20.0, and 18.9 mL/s at 1, 3, 6, and 12 months postoperatively. The postvoid residual urine volume also decreased from 189 mL preoperatively to 78, 78, 67, and 109 mL at 1, 3, 6, and 12 months postoperatively.
  
  
  CONCLUSIONS
  Photoselective laser vaporization of the prostate is safe and efficacious, with durable results for men with symptomatic benign prostatic hyperplasia and large-volume prostates.
authors.affiliation: Department of Urology, New York Presbyterian Hospital Cornell University Weill Medical College, New York, New York 10021, USA.
authors.forename: Jaspreet S
authors.initials: JS
authors.lastname: Sandhu
authors.forename: Casey
authors.initials: C
authors.lastname: Ng
authors.forename: Brian A
authors.initials: BA
authors.lastname: Vanderbrink
authors.forename: Celeste
authors.initials: C
authors.lastname: Egan
authors.forename: Steven A
authors.initials: SA
authors.lastname: Kaplan
authors.forename: Alexis E
authors.initials: AE
authors.lastname: Te
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D006801:Humans; D053685:Laser Therapy; D008297:Male; D008875:Middle Aged; D010710:Phosphates; D011470:Prostatic Hyperplasia / Q000628:therapy*; D014025:Titanium
chemical_list: D010710:Phosphates; C064806:potassium titanylphosphate; D014025:Titanium